» Articles » PMID: 15681406

Interactions Between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1

Overview
Journal J Virol
Date 2005 Feb 1
PMID 15681406
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Antibodies can prevent lentivirus infections in animals and may play a role in controlling viral burden in established infection. In preventing and particularly in controlling infection, antibodies likely function in the presence of large quantities of virus. In this study, we explored the mechanisms by which antibodies neutralize large inocula of human immunodeficiency virus type 1 (HIV-1) on different target cells. Immunoglobulin G (IgG) from HIV-infected patients was tested for neutralizing activity against primary R5 strains of HIV-1 at inocula ranging from 100 to 20,000 50% tissue culture infective doses. At all virus inocula, inhibition by antibody was enhanced when target cells for virus growth were monocyte-depleted, peripheral blood mononuclear cells (PBMCs) rather than CD4(+) lymphocytes. However, enhanced inhibition on PBMCs was greatest with larger amounts of virus. Depleting PBMCs of natural killer (NK) cells, which express Fc receptors for IgG (FcgammaRs), abrogated the enhanced antibody inhibition, whereas adding NK cells to CD4(+) lymphocytes restored inhibition. There was no enhanced inhibition on PBMCs when F(ab')(2) was used. Further experiments demonstrated that the release of beta-chemokines, most likely through FcgammaR triggering of NK cells, contributed modestly to the antiviral activity of antibody on PBMCs and that antibody-coated virus adsorbed to uninfected cells provided a target for NK cell-mediated inhibition of HIV-1. These results indicate that Fc-FcgammaR interactions enhance the ability of antibody to neutralize HIV-1. Since FcgammaR-bearing cells are always present in vivo, FcgammaR-mediated antibody function may play a role in the ability of antibody to control lentivirus infection.

Citing Articles

Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.

Gach J, Bouzin M, Wong M, Chromikova V, Gorlani A, Yu K PLoS Pathog. 2017; 13(12):e1006793.

PMID: 29281723 PMC: 5760106. DOI: 10.1371/journal.ppat.1006793.


Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

B Gilbert P, Juraska M, deCamp A, Karuna S, Edupuganti S, Mgodi N Stat Commun Infect Dis. 2017; 9(1).

PMID: 29218117 PMC: 5714515. DOI: 10.1515/scid-2016-0001.


In vitro inhibition of HIV-1 replication in autologous CD4 T cells indicates viral containment by multifactorial mechanisms.

Tu T, Zhan J, Mou D, Li W, Su B, Zhang T Virol Sin. 2017; 32(6):485-494.

PMID: 28918477 PMC: 6599175. DOI: 10.1007/s12250-017-3992-9.


Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions.

Dowall S, Graham V, Corbin-Lickfett K, Empig C, Schlunegger K, Bruce C J Immunol Res. 2015; 2015:347903.

PMID: 25815346 PMC: 4359806. DOI: 10.1155/2015/347903.


Functions of Antibodies.

Forthal D Microbiol Spectr. 2014; 2(4):1-17.

PMID: 25215264 PMC: 4159104.


References
1.
Lafont V, Liautard J, Liautard J, Favero J . Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J Immunol. 2001; 166(12):7190-9. DOI: 10.4049/jimmunol.166.12.7190. View

2.
Forthal D, Landucci G, Keenan B . Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses. 2001; 17(6):553-61. DOI: 10.1089/08892220151126661. View

3.
Hofmann-Lehmann R, Vlasak J, Rasmussen R, Smith B, Baba T, Liska V . Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol. 2001; 75(16):7470-80. PMC: 114982. DOI: 10.1128/JVI.75.16.7470-7480.2001. View

4.
Parren P, Marx P, Hessell A, Luckay A, Harouse J, Cheng-Mayer C . Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001; 75(17):8340-7. PMC: 115078. DOI: 10.1128/jvi.75.17.8340-8347.2001. View

5.
Dijstelbloem H, van de Winkel J, Kallenberg C . Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 2001; 22(9):510-6. DOI: 10.1016/s1471-4906(01)02014-2. View